Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-World Effectiveness and Safety of Deutetrabenazine in Chinese Patients With Chorea Associated With Huntington's Disease
NCT07601516Phase 4Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Feb 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of deutetrabenazine in chorea, sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Change From Baseline in Total Maximal Chorea (TMC) Score in Participants Receiving >=24 mg/Day at 16 weeks. Started Feb 2024; status: completed.
02
Drugs
deutetrabenazine
03
Conditions
chorea
Beyond the preview
Go deeper on NCT07601516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07601516.